Eye problems in breast cancer patients treated with tamoxifen View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-03

AUTHORS

Annlia Paganini-Hill, Linda J Clark

ABSTRACT

BACKGROUND: Tamoxifen is an oral anti-estrogen used in the treatment of breast cancer and recently approved to reduce the incidence of breast cancer in high risk women. As a large clinical trial of tamoxifen has reported an increased risk of cataract, we conducted a study of women with breast cancer to evaluate the association of tamoxifen with cataracts and other eye problems. METHODS: We attempted to recruit previously interviewed patients who were cases in a population-based case-control study of 2653 women with primary breast cancer diagnosed between 1987 and 1996 at ages 55-72 years in Los Angeles County, California, USA. In November 1997, each case was mailed a questionnaire to ascertain self-reported incidence of eye diseases and Amsler grid test scores. Information from 1297 women aged 57-75 years of age was analyzed. Women reporting treatment with tamoxifen were categorized as standard-term users (4-5 years), short-term users (<4 years), or long-term users (6+ years) and compared to non-users. All p-values, relative risks, and confidence intervals for differences in eye problems and grid test results are adjusted for age and stage of disease at diagnosis. FINDINGS: Standard-term and long-term users of tamoxifen more frequently reported developing cataracts than non-users (18.2%, 21.4% vs. 14.8%). The relative risk was 1.40 (95% confidence interval 0.94-2.10) for standard-term users and 1.70 (1.11-2.59) for long-term users. Tamoxifen use was unrelated to frequency of glaucoma or macular degeneration or to Amsler grid test results. INTERPRETATION: Our study suggests that five or more years of tamoxifen use increases risk of cataracts. Healthy women considering tamoxifen use to reduce risk of breast cancer should be advised of the possibility of cataract development. Women choosing such therapy should be diligent about receiving regular ocular exams. More... »

PAGES

167-172

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1006342300291

DOI

http://dx.doi.org/10.1023/a:1006342300291

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053062817

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10845279


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cataract", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Eye Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Southern California", 
          "id": "https://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paganini-Hill", 
        "givenName": "Annlia", 
        "id": "sg:person.01032313301.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032313301.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southern California", 
          "id": "https://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clark", 
        "givenName": "Linda J", 
        "id": "sg:person.01334140055.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334140055.98"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1172/jci117514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018622434"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0161-6420(96)30431-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039249711"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0042-6989(94)90099-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039738451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0042-6989(94)90099-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039738451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9394(99)80190-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049049615"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/90.18.1371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049883062"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006254-200007000-00022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060260386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006254-200007000-00022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060260386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006254-200007000-00022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060260386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081767724", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082773348", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.3.1018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082882762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083051131", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-03", 
    "datePublishedReg": "2000-03-01", 
    "description": "BACKGROUND: Tamoxifen is an oral anti-estrogen used in the treatment of breast cancer and recently approved to reduce the incidence of breast cancer in high risk women. As a large clinical trial of tamoxifen has reported an increased risk of cataract, we conducted a study of women with breast cancer to evaluate the association of tamoxifen with cataracts and other eye problems.\nMETHODS: We attempted to recruit previously interviewed patients who were cases in a population-based case-control study of 2653 women with primary breast cancer diagnosed between 1987 and 1996 at ages 55-72 years in Los Angeles County, California, USA. In November 1997, each case was mailed a questionnaire to ascertain self-reported incidence of eye diseases and Amsler grid test scores. Information from 1297 women aged 57-75 years of age was analyzed. Women reporting treatment with tamoxifen were categorized as standard-term users (4-5 years), short-term users (<4 years), or long-term users (6+ years) and compared to non-users. All p-values, relative risks, and confidence intervals for differences in eye problems and grid test results are adjusted for age and stage of disease at diagnosis.\nFINDINGS: Standard-term and long-term users of tamoxifen more frequently reported developing cataracts than non-users (18.2%, 21.4% vs. 14.8%). The relative risk was 1.40 (95% confidence interval 0.94-2.10) for standard-term users and 1.70 (1.11-2.59) for long-term users. Tamoxifen use was unrelated to frequency of glaucoma or macular degeneration or to Amsler grid test results.\nINTERPRETATION: Our study suggests that five or more years of tamoxifen use increases risk of cataracts. Healthy women considering tamoxifen use to reduce risk of breast cancer should be advised of the possibility of cataract development. Women choosing such therapy should be diligent about receiving regular ocular exams.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1006342300291", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2435384", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "60"
      }
    ], 
    "name": "Eye problems in breast cancer patients treated with tamoxifen", 
    "pagination": "167-172", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fcc040a36559c19b4d5bc426f40477dc0236d46a2f94e2e29c1790b94065afee"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10845279"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1006342300291"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053062817"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1006342300291", 
      "https://app.dimensions.ai/details/publication/pub.1053062817"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000501.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023/A:1006342300291"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1006342300291'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1006342300291'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1006342300291'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1006342300291'


 

This table displays all metadata directly associated to this object as RDF triples.

157 TRIPLES      21 PREDICATES      52 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1006342300291 schema:about N0a3d4ac92420400b83dab04bf9151d19
2 N1470eea29c604e5c8b79a3cf8d79459f
3 N3c5e9456767641f0997edd1452e1c6bd
4 N3df74af7b21c4ec18eb9e3a78f043fc8
5 N3e202e9439a446f8b0886e9454a6d339
6 N58e02b9dc9d546a792153582e1f33e17
7 N5d7f9a628f6e432eac0cde281f6e1929
8 N7b30fb352cc14deeb37f04828e5f389d
9 N8cff6a4886254f95b7e48bb7ebe4d29d
10 Na19727048a6d4895a6b0f652aa6e5024
11 Nad89056515e941bba6bdebd4c464ce3c
12 Nc3d36d7db43e4641a2e360fb7c8f8632
13 Ndf7b5accd7a54e179b3bbbc70534cc40
14 anzsrc-for:11
15 anzsrc-for:1117
16 schema:author N09c876f0b48a42d3a4a97d3d15082e01
17 schema:citation https://app.dimensions.ai/details/publication/pub.1081767724
18 https://app.dimensions.ai/details/publication/pub.1082773348
19 https://app.dimensions.ai/details/publication/pub.1083051131
20 https://doi.org/10.1016/0042-6989(94)90099-x
21 https://doi.org/10.1016/s0002-9394(99)80190-1
22 https://doi.org/10.1016/s0161-6420(96)30431-4
23 https://doi.org/10.1093/jnci/90.18.1371
24 https://doi.org/10.1097/00006254-200007000-00022
25 https://doi.org/10.1172/jci117514
26 https://doi.org/10.1200/jco.1996.14.3.1018
27 schema:datePublished 2000-03
28 schema:datePublishedReg 2000-03-01
29 schema:description BACKGROUND: Tamoxifen is an oral anti-estrogen used in the treatment of breast cancer and recently approved to reduce the incidence of breast cancer in high risk women. As a large clinical trial of tamoxifen has reported an increased risk of cataract, we conducted a study of women with breast cancer to evaluate the association of tamoxifen with cataracts and other eye problems. METHODS: We attempted to recruit previously interviewed patients who were cases in a population-based case-control study of 2653 women with primary breast cancer diagnosed between 1987 and 1996 at ages 55-72 years in Los Angeles County, California, USA. In November 1997, each case was mailed a questionnaire to ascertain self-reported incidence of eye diseases and Amsler grid test scores. Information from 1297 women aged 57-75 years of age was analyzed. Women reporting treatment with tamoxifen were categorized as standard-term users (4-5 years), short-term users (<4 years), or long-term users (6+ years) and compared to non-users. All p-values, relative risks, and confidence intervals for differences in eye problems and grid test results are adjusted for age and stage of disease at diagnosis. FINDINGS: Standard-term and long-term users of tamoxifen more frequently reported developing cataracts than non-users (18.2%, 21.4% vs. 14.8%). The relative risk was 1.40 (95% confidence interval 0.94-2.10) for standard-term users and 1.70 (1.11-2.59) for long-term users. Tamoxifen use was unrelated to frequency of glaucoma or macular degeneration or to Amsler grid test results. INTERPRETATION: Our study suggests that five or more years of tamoxifen use increases risk of cataracts. Healthy women considering tamoxifen use to reduce risk of breast cancer should be advised of the possibility of cataract development. Women choosing such therapy should be diligent about receiving regular ocular exams.
30 schema:genre research_article
31 schema:inLanguage en
32 schema:isAccessibleForFree false
33 schema:isPartOf N158547b28a6a4b128cab0de9c600be8b
34 Nabd32d8c70c94b239879aaa10ef26bf0
35 sg:journal.1092777
36 schema:name Eye problems in breast cancer patients treated with tamoxifen
37 schema:pagination 167-172
38 schema:productId N1f80b48c5aee40dfb809d5409f1ed005
39 N526c27c302c94817ab75330cb4a3d00c
40 N5569844ed9c242e297433d26ab9651ac
41 N5b6fbe3cad5545a091f68dd4cadc460f
42 Nd074d8675f0e4b34b8bbfd595324515d
43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053062817
44 https://doi.org/10.1023/a:1006342300291
45 schema:sdDatePublished 2019-04-10T14:07
46 schema:sdLicense https://scigraph.springernature.com/explorer/license/
47 schema:sdPublisher N4ea02579a18141d3ba5686efb828d839
48 schema:url http://link.springer.com/10.1023/A:1006342300291
49 sgo:license sg:explorer/license/
50 sgo:sdDataset articles
51 rdf:type schema:ScholarlyArticle
52 N05620007800041bb9a7ecdd8e1cad52c rdf:first sg:person.01334140055.98
53 rdf:rest rdf:nil
54 N09c876f0b48a42d3a4a97d3d15082e01 rdf:first sg:person.01032313301.19
55 rdf:rest N05620007800041bb9a7ecdd8e1cad52c
56 N0a3d4ac92420400b83dab04bf9151d19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Time Factors
58 rdf:type schema:DefinedTerm
59 N1470eea29c604e5c8b79a3cf8d79459f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Tamoxifen
61 rdf:type schema:DefinedTerm
62 N158547b28a6a4b128cab0de9c600be8b schema:issueNumber 2
63 rdf:type schema:PublicationIssue
64 N1f80b48c5aee40dfb809d5409f1ed005 schema:name doi
65 schema:value 10.1023/a:1006342300291
66 rdf:type schema:PropertyValue
67 N3c5e9456767641f0997edd1452e1c6bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Follow-Up Studies
69 rdf:type schema:DefinedTerm
70 N3df74af7b21c4ec18eb9e3a78f043fc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Middle Aged
72 rdf:type schema:DefinedTerm
73 N3e202e9439a446f8b0886e9454a6d339 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Humans
75 rdf:type schema:DefinedTerm
76 N4ea02579a18141d3ba5686efb828d839 schema:name Springer Nature - SN SciGraph project
77 rdf:type schema:Organization
78 N526c27c302c94817ab75330cb4a3d00c schema:name readcube_id
79 schema:value fcc040a36559c19b4d5bc426f40477dc0236d46a2f94e2e29c1790b94065afee
80 rdf:type schema:PropertyValue
81 N5569844ed9c242e297433d26ab9651ac schema:name dimensions_id
82 schema:value pub.1053062817
83 rdf:type schema:PropertyValue
84 N58e02b9dc9d546a792153582e1f33e17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Antineoplastic Agents, Hormonal
86 rdf:type schema:DefinedTerm
87 N5b6fbe3cad5545a091f68dd4cadc460f schema:name pubmed_id
88 schema:value 10845279
89 rdf:type schema:PropertyValue
90 N5d7f9a628f6e432eac0cde281f6e1929 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Female
92 rdf:type schema:DefinedTerm
93 N7b30fb352cc14deeb37f04828e5f389d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Eye Diseases
95 rdf:type schema:DefinedTerm
96 N8cff6a4886254f95b7e48bb7ebe4d29d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Breast Neoplasms
98 rdf:type schema:DefinedTerm
99 Na19727048a6d4895a6b0f652aa6e5024 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Risk Assessment
101 rdf:type schema:DefinedTerm
102 Nabd32d8c70c94b239879aaa10ef26bf0 schema:volumeNumber 60
103 rdf:type schema:PublicationVolume
104 Nad89056515e941bba6bdebd4c464ce3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Cataract
106 rdf:type schema:DefinedTerm
107 Nc3d36d7db43e4641a2e360fb7c8f8632 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Aged
109 rdf:type schema:DefinedTerm
110 Nd074d8675f0e4b34b8bbfd595324515d schema:name nlm_unique_id
111 schema:value 8111104
112 rdf:type schema:PropertyValue
113 Ndf7b5accd7a54e179b3bbbc70534cc40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Incidence
115 rdf:type schema:DefinedTerm
116 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
117 schema:name Medical and Health Sciences
118 rdf:type schema:DefinedTerm
119 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
120 schema:name Public Health and Health Services
121 rdf:type schema:DefinedTerm
122 sg:grant.2435384 http://pending.schema.org/fundedItem sg:pub.10.1023/a:1006342300291
123 rdf:type schema:MonetaryGrant
124 sg:journal.1092777 schema:issn 0167-6806
125 1573-7217
126 schema:name Breast Cancer Research and Treatment
127 rdf:type schema:Periodical
128 sg:person.01032313301.19 schema:affiliation https://www.grid.ac/institutes/grid.42505.36
129 schema:familyName Paganini-Hill
130 schema:givenName Annlia
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032313301.19
132 rdf:type schema:Person
133 sg:person.01334140055.98 schema:affiliation https://www.grid.ac/institutes/grid.42505.36
134 schema:familyName Clark
135 schema:givenName Linda J
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334140055.98
137 rdf:type schema:Person
138 https://app.dimensions.ai/details/publication/pub.1081767724 schema:CreativeWork
139 https://app.dimensions.ai/details/publication/pub.1082773348 schema:CreativeWork
140 https://app.dimensions.ai/details/publication/pub.1083051131 schema:CreativeWork
141 https://doi.org/10.1016/0042-6989(94)90099-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1039738451
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1016/s0002-9394(99)80190-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049049615
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1016/s0161-6420(96)30431-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039249711
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1093/jnci/90.18.1371 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049883062
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1097/00006254-200007000-00022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060260386
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1172/jci117514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018622434
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1200/jco.1996.14.3.1018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082882762
154 rdf:type schema:CreativeWork
155 https://www.grid.ac/institutes/grid.42505.36 schema:alternateName University of Southern California
156 schema:name Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
157 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...